Gland Pharma
Gland Pharma Limited, commonly referred to as Gland Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Established in 1978, the company has made significant strides in the development and manufacturing of high-quality injectable pharmaceuticals, particularly in the areas of oncology, anaesthesia, and critical care. With a strong presence in both domestic and international markets, Gland Pharma has earned a reputation for its robust product portfolio, which includes a range of generic injectables and complex formulations. The company is recognised for its commitment to quality and innovation, having achieved several key milestones, including successful partnerships with global healthcare providers. Gland Pharma's dedication to excellence positions it as a leader in the injectable segment, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Gland Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gland Pharma's score of 21 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gland Pharma's reported carbon emissions
In 2024, Gland Pharma reported total carbon emissions of approximately 15,736,000 kg CO2e for Scope 1 and about 81,154,000 kg CO2e for Scope 2, resulting in a combined total of approximately 96,890,000 kg CO2e. This marks a slight increase in emissions compared to 2023, where Scope 1 emissions were about 11,929,600 kg CO2e and Scope 2 emissions were approximately 80,669,600 kg CO2e, leading to a total of around 92,599,200 kg CO2e. In 2022, the company recorded Scope 1 emissions of about 12,579,300 kg CO2e and Scope 2 emissions of approximately 78,475,200 kg CO2e, resulting in a total of around 91,054,500 kg CO2e. Gland Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The company has reported emissions data for Scope 1 and Scope 2 but has not provided information on Scope 3 emissions. Their emissions intensity per rupee of turnover has shown some variation, with values of 0.05237 for 2024 and 0.05728 for 2023, indicating a focus on aligning emissions with revenue growth. Overall, Gland Pharma's emissions data reflects their ongoing operations and highlights the need for further climate action and transparency in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,579,300 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,475,200 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gland Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
